Metabolic Regulation Peptides Bioactive Toxin-Derived Peptides Tumor-Associated Antigen Peptides Nuclear Localization Signals (NLS) Cell-Penetrating Peptides (CPPs) Neurodegenerative Disease Research Peptides Melanogenesis Modulation Anti-Aging & Skin Remodeling Gastrin, GRP & Bombesin Peptides Somatostatin Analogs DPPIV/CD26 Peptides Kinase Activity Modulators Caspase Substrates & Inhibitors Viral Protease Substrates Antiviral Peptides Antimicrobial Peptides Cardiovascular Peptides Immunomodulatory Peptides Calcitonin & CGRP Family Peptides Incretin & Metabolic Peptides Parathyroid Hormone (PTH) Growth Hormone GnRH Analogues/Antagonists Pain and Inflammation Modulation Pituitary Hormones Neurotransmitters/Neuropeptides Standard Fmoc-Amino Acids D-Form Amino Acids Resins Peptide Coupling Reagents & Additives Specialty Peptide Building Blocks Pseudoproline Dipeptides Phenylalanine & Tryptophan Unusual Amino Acids & Analogs Newly Launched Small-Molecule Specialties Impurity Analysis & Bioactivity Research Special Offers Peptide Synthesis Chemical Synthesis ADMET Profiling Service AlanMolecularAI AlanDockAI Linear Peptide Optimization Cyclic Peptide Optimization Task Management Knowledge Center News About Us Reagents & Custom Orders Aipower Platform
Sign in
Cart
Search
Home Product Peptide Catalog Products Cardiovascular Peptides Biotin-Angiotensin I Human | Biotinylated ACE Substrate

DESCRIPTION

Biotin-Angiotensin I, human is an N-terminally biotinylated derivative of the human Angiotensin I decapeptide. It combines the native DRVYIHPFHL sequence with a biotin affinity handle for capture, detection and peptide-processing studies.

The C-terminal His-Leu region recognized during ACE-dependent conversion remains intact, while the N-terminal chemistry is modified by biotinylation.

Product Information

PropertySpecification
Product NameBiotin-Angiotensin I, Human
Catalog No.AS2622
SequenceBiotin-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu
One-Letter SequenceBiotin-DRVYIHPFHL
Peptide Length10 amino-acid residues
Molecular FormulaC72H103N19O16S
Molecular WeightApproximately 1522.81 Da
ModificationN-terminal biotin
Research AreasACE processing, affinity capture, RAS peptide metabolism

Biotin Placement and ACE Processing

Native human Angiotensin I is converted to Angiotensin II through removal of its C-terminal His-Leu dipeptide by angiotensin-converting enzyme.

Because biotin is positioned at the opposite end of the sequence, this construct retains the native C-terminal ACE cleavage region. Enzymatic processing would generate a biotin-containing Angiotensin II-derived product while releasing His-Leu.

We recommend experimentally validating enzyme kinetics rather than assuming that N-terminal biotinylation leaves the catalytic parameters of native Angiotensin I completely unchanged.

Affinity-Based Research Applications

The biotin group allows interaction with streptavidin-based reagents and surfaces, supporting peptide capture, immobilization and detection workflows.

This makes Biotin-Angiotensin I useful for experiments that combine RAS peptide processing with affinity-based analytical methods.

Experimental Considerations

Biotinylated and unlabeled Angiotensin I should be treated as distinct molecular forms when quantitative ACE kinetics are compared. Reporter accessibility can also depend on the assay architecture and streptavidin surface density.

Custom labeling positions, spacers and related RAS peptides can be evaluated through our Chemical Peptide Synthesis capabilities.

Frequently Asked Questions

Where is biotin attached in this peptide?

The biotin group is attached at the N-terminus of the human Angiotensin I sequence.

Does Biotin-Angiotensin I contain the native ACE cleavage region?

Yes. The C-terminal His-Leu region of the Angiotensin I sequence is retained.

Research Use Only.

Biotin-Angiotensin I Human | Biotinylated ACE Substrate

Catalog No: AS2622

{{ getShowPrice() }} {{ getPrice() }}

Add to Cart Bulk Inquiry
{{ isCollect ? 'Cancel collection' : 'Collection' }}

Related Products

Submit